Enhanced software supports cell therapy and research organizations with added value, compliance aid
LAKEWOOD, Colo. - Wednesday, November 13th 2013 [ME NewsWire]
(BUSINESS WIRE)-- Terumo BCT has released updated software for the Quantum system as part of its ongoing goal to aid cell therapy companies and research organizations in current Good Manufacturing Practices (cGMP) and compliance with Part 11 of the Code of Federal Regulations (CFR).
KEY FACTS ABOUT QUANTUM SOFTWARE 2.0
Automates traditional manual reporting with electronic data capture for cell culture processes.
Keeps users informed with customized, remote alarm notifications, in the event of a disruption to cell culture processes.
Provides improved process control with user authentication, and tracking tasks and configuration changes performed by operators and administrators for enhanced traceability.
Restores the system to its prior running state after power failures, reinstating the most recent system task.
KEY FACTS ABOUT THE QUANTUM SYSTEM:
An automated cell culture platform that can help simplify the open, labor-intensive manual tasks associated with flask-based culture, helping improve the reproducibility and scalability of cell culturing processes to meet overall manufacturing requirements.
Available since 2010, the Quantum system is available in select markets.
KEY QUOTE:
Dave Flaten, Terumo BCT Vice President, Cell Processing "With technology so important to the growing field of regenerative medicine, Terumo BCT believes it is imperative we listen to our customers and support them every way we can. With the release of the latest Quantum software, we are providing an enhanced tool to help customers achieve their goals, drive process scalability and compliance, and further their commercial and research endeavors.”
KEY RESOURCES:
Quantum System Fact Sheet
Comparing Cell Culture Processes Video
NOTE: This software upgrade does not involve any changes to the Quantum device, cell expansion set or accessory sets.
About Terumo BCT:
Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction coupled with leading technologies in therapeutic apheresis and cell processing. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.
Contacts
Terumo BCT
Laura Fusco, +1-303-205-2546
Global Corporate Communications
press@terumobct.com
Permalink: http://me-newswire.net/news/9163/en
|
